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Abstract: The most important features that determine the vital role of bone include: a) a continuous supply of
calcium, which is indispensible for every cell of the entire organism at all times, and b) the delivery of circulating
blood cells and some adult stem cells to keep the body vigorous, ready for self-reparation, and continuously
rebuilding throughout life. These functions of bones are no less important than protecting the body cavities,
serving as mechanical levers connected to the muscles, and determining the  shape and dimensions of the entire
organism. The aim of this review was to address some basic cellular and molecular knowledge to better under-
stand the complex interactions of bone structural components. The apprehension of osteoblast differentiation
and its local regulation has substantially increased in recent years. It has been suggested that osteocytes, cells
within the bone matrix, act as regulatory mechanosensors. Therefore immobility as well as limited activity has
a dramatic effect on bone structure and influences a broad spectrum of bone physiology-related functions as well
as the functions of many other organs. Lifelong bone rebuilding is modulated through several pathways, includ-
ing the Wnt pathway that regulates bone formation and resorption. In the adult skeleton, bone is continuously
renewed in response to a variety of stimuli, such as the specific process of remodeling dependent on RANK/
/RANKL/OPG interactions. Better understanding of bone biology provides opportunities for the development
of more effective prevention and treatment modalities for a variety of bone diseases, including new approaches
to adult stem cell-based therapies. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 558–569)
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Introduction
The ‘Bone and Joint Decade’ was officially launched
on 13 January, 2000 at the headquarters of the World
Health Organization in Geneva. This global campaign
was designed to improve the quality of life of people
with musculoskeletal conditions such as joint diseas-
es, osteoporosis, osteoarthritis, rheumatoid arthritis,
lower back pain, spinal disorders, severe trauma to
the extremities, and crippling diseases and deformi-
ties in children. The goals were to advance the un-
derstanding and treatment of such conditions through
research, prevention, and education. The steady in-
crease in life expectancy resulting from advances in
medicine leads to an increased prevalence of muscu-
loskeletal disorders, which in turn causes an ever
greater socio-economic burden around the world as
the population ages. The aims of the campaign were
to raise awareness of the increasing societal impact
of musculoskeletal injuries and disorders, to empow-
er patients to participate in decisions about their care,
to increase funding for prevention activities and re-
search, and to promote research-based cost-effective
prevention and treatment [1].
Bone as an organ
The adult human skeleton is composed of 213 bones,
excluding the sesamoid bones [2, 3], and makes up
about 20 percent of body mass. There are four cate-
gories of bones: long bones, short bones, flat bones,
and irregular bones. The skeleton serves a variety of
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functions; the bones provide structural support for
the whole body, permit movement and locomotion by
providing levers for the muscles, protect internal or-
gans, provide continuous maintenance of mineral
homeostasis and acid-base balance, serve as a reser-
voir of growth factors and cytokines, and provide the
environment for hematopoiesis within the bone mar-
row (BM) spaces [4].
The adult human skeleton is composed of 80% cor-
tical (compact) bone and 20% trabecular (cancellous)
bone. Cortical bone has an outer periosteal and inner
endosteal surface (Figure 1). Periosteal surface activi-
ty is important for appositional growth and fracture
repair. Cortical bone and trabecular bone are normal-
ly formed in a lamellar pattern, in which collagen fibrils
are laid down in alternating orientations. The cortical
bone contains osteons (Haversian systems), which are
composed of a central canal (Haversian canal) sur-
rounded by lamellae of bone matrix. Within the lamel-
lae, there are osteocytes embedded in tiny spaces —
lacunae. The Haversian canal encompasses blood ves-
sels and nerves throughout the bone and communi-
cates with osteocytes in lacunae through canaliculi. The
periosteum, consisting of outer and inner fibrous lay-
ers, has an osteogenic potential and enables the bone
to enlarge [5]. The inside of bone is assembled by
a trabecular network (spongiosa) and harbors BM or
embryonic connective tissue. The spongiosa ensures
elasticity and stability of the skeleton and accounts for
the main part (about 70%) of bone metabolism [6].
Bone matrix is mostly composed of type I collagen,
trace amounts of types III and V, and FACIT collagens
at certain stages of bone formation determining col-
lagen fibril diameter. FACIT stands for Fibril-Asso-
ciated Collagens with Interrupted Triple Helices,
a group of nonfibrillar collagens that serve as molecu-
lar bridges important for the organization and stability
of extracellular matrix. Members of this family include
collagens IX, XII, XIV, XIX, XX, and XXI. Bone ma-
trix also contains noncollagenous proteins constituting
10% to 15% of total bone protein. Approximately 25%
of noncollagenous protein is derived exogenously, in-
cluding serum albumin and a2-HS-glycoprotein, which
bind to hydroxyapatite. Serum-derived noncollagenous
proteins participate in the regulation of matrix mineral-
ization, and a2-HS-glycoprotein regulates bone cell pro-
liferation. Bone is composed of mineral (50% to 70%)
and organic (20% to 40%) matrix, 5% to 10% of water,
and < 3% of lipids. The mineral content of bone is mostly
hydroxyapatite [Ca10(PO4)6(OH)2] with small amounts
of carbonate, magnesium and acid phosphate. The re-
maining organic component consists of non-structural
proteins like growth factors, blood proteins, osteonec-
tin and osteocalcin.
One of the important functions of the bone is
mechanosensation, though the action of osteocyte-
osteoblast/lining cell syncytium. Osteocytes transduce
stress signals, induced by bending or stretching of
bone, into biologic activity. Flow of canalicular fluid
in response to external forces induces a variety of re-
sponses within osteocytes. Rapid movements of bone
calcium across the filipodial gap junctions stimulate
transmission of information between osteoblasts on
the bone surface and osteocytes within [7]. Signaling
mechanisms involved in mechanotransduction include
prostaglandin E2, cyclo-oxygenase 2, various kinases,
Runx2, and nitrous oxide. There is a theory [8] that
mechanoreceptors in bone can transduce mechani-
cal stimuli into anabolic or catabolic signals for tis-
sues remodeling. Immobility as well as limited activi-
ty has a dramatic effect on bone resorption and many
organs. This is modulated by major pathways that
couple bone formation and resorption, such as the
Wnt (Wingless-type MMTV integration site) path-
Figure 1. Bone anatomo-functional compartmentalization
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way [9]. The presence of empty lacunae in aging bone
suggests that osteocytes may undergo apoptosis, prob-
ably caused by disruption of their intercellular gap
junctions or cell–matrix interactions [10]. Osteocyte
apoptosis in response to estrogen deficiency or glu-
cocorticoid treatment is harmful to bone structure.
Estrogen and bisphosphonate therapy and physiologic
loading of bone may help prevent osteoblast and os-
teocyte apoptosis [11].
Bone remodeling
Bone remodeling begins before birth and continues
until the organism’s death. In adults about 25% of
trabecular and 3% of cortical bone is replaced each
year [12]. Bone remodeling increases in perimeno-
pausal and early postmenopausal women and then
slows down with further aging of both genders, but
continues at a faster rate than in the premenopausal
period. Adolescence is a critical time for determin-
ing peak bone mass. During this period, bone forma-
tion prevails over resorption, and approximately 40%
of the total bone mass is accumulated. Several fac-
tors affect the accretion of bone mass during adoles-
cence. While genetic predisposition, age, race, and
ethnicity cannot be modified, other factors impact-
ing bone such as nutrition, physical activity and life-
style choices can be altered [13].
All bones in the mammalian skeleton, with the
exception of the bones of the calvaria, mandible, part
of the maxilla and clavicle are preformed in cartilage
moulds from mesenchymal progenitors. Osteoblasts,
which differentiate from progenitors in a collar of
connective tissue around the middle of the bones
where vascular invasion takes place, follow the en-
dothelial cells and lay down bone matrix on the sur-
faces of these islands of cartilage to form bone struts
or trabeculae [14].
Osteoclast precursors (OCPs), derived from pro-
genitors in the spleen and liver, are attracted from
blood in the invading blood vessels close to the newly
formed bone trabeculae. In an adult organism, os-
teoclasts are derived from hematopoietic stem cells
and share precursors with macrophages, whereas cells
of the osteoblast lineage such as stromal cells, bone
lining cells, osteoprogenitors, preosteoblasts, osteo-
blasts and osteocytes are derived from mesenchymal
stem cells, which can also differentiate into fibroblasts,
chondrocytes, myoblasts and adipocytes. Osteocytes,
the terminally differentiated cells of the osteoblast
lineage, account for over 90% of all bone cells.
Osteoclastic resorption prevents the development
of osteopetrosis, a congenital defect of endochondral
ossification, which occurs if osteoclasts fail to form
or have impaired activity [15]. As the cartilaginous
centers of the growing bones are removed and re-
placed by bone and BM, condensations of proliferat-
ing and prehypertrophic chondrocytes form close to the
ends of long bones, where along with a layer of hyper-
trophic chondrocytes they constitute the epiphyseal
growth plates. This process, called endochondral ossifi-
cation, requires expression of Runx2, the master tran-
scription factor that regulates bone formation, by mes-
enchymal osteoblast precursor cells [16]. Hypertrophic
chondrocytes express RANKL, OPG and RANK.
Osteoclast formation, activation and resorption are
regulated by the ratio of receptor activator of NF-kB
ligand (RANKL) to osteoprotegerin (OPG), IL-1 and
IL-6, colony-stimulating factor (CSF), parathyroid
hormone, 1,25-dihydroxyvitamin D, and calcitonin
[17]. Resorbing osteoclasts secrete hydrogen ions via
H+-ATPase proton pumps and chloride channels in
their cell membranes into the resorbing compartment
to lower the pH within the bone-resorbing space  to
as low as 4.5, which helps mobilize bone minerals.
Resorbing osteoclasts secrete tartrate-resistant acid
phosphatase, cathepsin K, matrix metalloproteinase 9,
and gelatinase from cytoplasmic lysosomes to digest
the organic matrix, resulting in the formation of sau-
cer-shaped Howship’s lacunae on the surface of tra-
becular bone and Haversian canals in cortical bone.
The resorption phase is completed by mononuclear
cells after the multinucleated osteoclasts undergo
apoptosis [18]. Resorption is followed by osteoblast
activation and formation of osteoid, which fills the
cavities over a period of about three months [19].
Bone remodeling is controlled by a system compris-
ing three key participants: RANK, its ligand RANKL,
and a decoy receptor OPG. RANK was discovered by
Anderson et al. [20] by directly sequencing cDNA from
a human BM-derived myeloid dendritic cell. Osteoclas-
togenesis precedes with the expression of RANKL by
bone lining cells, which in turn binds to the RANK that
exists as a surface receptor on the membrane of pre-
osteoclasts. The receptor–ligand binding promotes an
intricate and distinct signaling cascade for osteoclast ac-
tivation and commitment [21, 22]. The expression of
RANKL is up-regulated in the presence of interleukin-1
(IL-1), tumor necrosis factor α (TNF-α) and vitamin
D, whereas transforming growth factor β (TGFβ) and
estrogens have an opposite effect.
Understanding the osteoclast activation process
is one of the most important discoveries in bone biol-
ogy of recent years [23]. RANKL is a member of the
tumor necrosis factor family, and is the most impor-
tant cytokine involved in the final stages of osteoclast
maturation and activity. The co-ordinated action of
bone cells is designated as the Basic Multicellular Unit
(BMU). Although there are many systemic factors
that initiate osteoclastogenesis, they all appear to work
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via the final common pathway by increasing produc-
tion of RANKL by osteoblasts [23]. The action of
RANKL on osteoclasts is opposed by the soluble re-
ceptor OPG, which belongs to the tumor necrosis fac-
tor (TNF) receptor family [23] and is secreted by os-
teoblasts and stromal cells. Cells of the osteoblast lin-
eage control the formation and activity of osteoclasts,
which, in turn, are responsible for the initiation and
execution of resorption at remodeling sites. There is
a period of bone formation mediated by osteoblasts,
followed by full mineralization of the newly formed
bone matrix [24]. Bone formation takes approximately
4–6 months to complete. Osteocytes, the terminally
differentiated osteoblasts, become embedded in the
osteoid matrix in which they were laying down.
Discovery of the RANKL/RANK/OPG system has
been one of the most important advances in bone bi-
ology in recent years. This signaling system is essen-
tial for skeletal homeostasis, and its disruption leads
to changes of bone resorption in vitro and in animal
models [25–27] of most bone diseases. OPG protects
bone from excessive resorption by binding to RANKL
and preventing it from binding to RANK [28]. OPG
acts as a decoy receptor [29]. It is known that there is
an ongoing bone formation despite the absence of
functional osteoclasts and reduced bone resorption
[30]. A hypothetical agent that could inhibit bone re-
sorption but allow continuous bone formation would
have a greater effect on bone mass and bone quality
than any currently available agent.
RANKL is a homotrimeric, typically membrane-
bound, protein present on osteoblastic and activated
T cells. It can be also secreted by some cells, such as
activated T cells [31]. Most of the factors known to
stimulate osteoclast formation and activity induce
RANKL expression by osteoblastic stromal cells.
RANKL expression increases in response to a variety
of pro-resorptive signals such as proinflammatory
cytokines, glucocorticoids, estrogen deficiency and
PTH excess [32]. RANKL binds to the RANK recep-
tor which is expressed on osteoclasts and their pre-
cursors. RANKL is a critical stimulator of the differ-
entiation and activity of osteoclasts and thus it plays
a critical role in the promotion of bone resorption.
OPG is a decoy receptor for RANKL that is se-
creted by osteoblasts, and to a lesser extent by other
stroma-derived cells, including those in the heart, kid-
ney, liver, and spleen. Most of the factors that induce
RANKL expression by osteoblasts also regulate OPG
expression [33]. Osteoclast numbers and its activity
can increase in response to a higher RANKL/OPG
ratio. A change in both leads to a change in favour of
RANKL. The discovery of RANKL, RANK and OPG
has led to the development of specific inhibitors of
RANKL, some of which, such as OPG and a mono-
clonal antibody to RANKL, have been tested in hu-
mans in clinical trials with successful inhibition of bone
resorption.
Upon the completion of bone resorption, resorption
cavities contain a variety of mononuclear cells, including
monocytes, osteocytes released from bone matrix, and
preosteoblasts recruited to begin new bone formation.
Coupling signals to induce new bone formation include
bone matrix-derived factors such as TGF-b, IGF-1, IGF-2,
bone morphogenetic proteins (BMPs), PDGF, or fibro-
blast growth factor. The phase of bone resorption is me-
diated by the strain gradient in the lacunae [34].
Osteoblasts synthesize new collagenous organic
matrix and regulate mineralization of matrix by re-
leasing small, membrane-bound matrix vesicles that
concentrate calcium and phosphate, and enzymati-
cally destroy mineralization inhibitors such as pyro-
phosphate and proteoglycans. Osteoblasts surround-
ed by and buried within matrix become osteocytes.
They form an extensive canalicular network with bone
surface lining cells, osteoblasts, and other osteocytes,
maintained by gap junctions between the cytoplas-
mic processes extending from the osteocytes. The os-
teocyte network within the bone serves as a function-
al syncytium. At the completion of bone formation,
approximately 50% to 70% of osteoblasts undergo
apoptosis, while a smaller proportion become osteo-
cytes or bone-lining cells. Bone-lining cells may regu-
late the influx and efflux of mineral ions in and out of
bone extracellular fluid, thereby serving as a blood-
-bone barrier. They retain the ability to re-differenti-
ate into osteoblasts upon exposure to parathyroid
hormone or mechanical forces. Bone-lining cells with-
in the endosteum lift off the surface of bone before
bone resorption to form discrete bone remodeling
compartments with a specialized microenvironment
[35]. The remodeling process is essentially the same
in cortical and trabecular bone.
The intensity of bone resorption depends on os-
teoclast secretion of hydrogen ions and cathepsin K
enzyme. H+ ions acidify the resorption compartment
beneath osteoclasts to dissolve the mineral compo-
nent of bone matrix, whereas cathepsin K digests the
proteinaceous matrix. Osteoclasts bind to bone ma-
trix via integrin receptors in the osteoclast membrane
linking to bone matrix peptides. The b1 family of in-
tegrin receptors in osteoclasts binds to collagen, fi-
bronectin and laminin, but the main integrin recep-
tor facilitating bone resorption is the avb3 integrin. The
ligands for the avb3 integrin include osteopontin
 and
bone sialoprotein [36].
Binding of osteoclasts to bone matrix causes their
polarization. The bone resorbing surface develops
a ruffled border when acidified vesicles that contain
matrix metalloproteinases and cathepsin K are trans-
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ported via microtubules to fuse with the membrane.
The ruffled border secretes H+ ions via H+-ATPase
and chloride channels and causes exocytosis of cathe-
psin K and other enzymes in the acidified vesicles.
Ruffling of the cytoplasmic membrane increases the
area of the cell surface for secretion of the proteolyt-
ic enzyme, cathepsin K, and hydrochloric acid [37].
By the sealing and secretory mechanism, osteoclasts
simultaneously degrade the matrix and dissolve the
mineral of bone, while protecting neighboring cells
from the harmful effects of HCl. Actively resorbing
osteoclasts form podosomes that allows them to be
firmly attached to bone matrix, rather than being fo-
cally adherent, as with most other cells. Podosomes
are composed of an actin core surrounded by avb3 in-
tegrins and associated cytoskeletal proteins.
The rate of bone remodeling and the number of
remodeling sites are increased in a variety of patho-
logic conditions affecting the skeleton, including post-
menopausal osteoporosis, hyperparathyroidism and
rheumatoid arthritis. In these disorders, the local and/
/or systemic alterations in the levels of hormones or
pro-inflammatory cytokines stimulate bone resorption
[38]. The induction of bone resorption is regulated
predominantly by indirect mechanisms that involve
upregulation of the expression of M-CSF and RANKL
by osteoblastic and other cells. Osteoclasts are not
simply bone resorbing cells, but they also regulate
osteoblast functions, mediate the egression of hemato-
poietic stems from the marrow into the blood [39],
and function as immunomodulators in pathologic
states [40].
Calcium reservoir
Bone is regarded as a mineral reservoir releasing cal-
cium and phosphate in response to hormones secret-
ed from remote organs [41]. Significant elements of
bone are Ca2+ and Pi [42]. Precise control of plasma
calcium (Ca2+) and phosphate (Pi) levels is essential
to the performance of many vital physiological func-
tions [43]. Muscle contraction, blood clotting and
neuronal excitation all require Ca2+, whereas Pi, as
a component of membrane lipids and backbone of
DNA, is crucial to intracellular signaling. Several or-
gans contribute to the exquisite regulation of Ca2+
and Pi homeostasis by facilitating intestinal absorp-
tion, bone (de)mineralization, and renal excretion/
/reabsorption. Regulation of these processes occurs
by a number of hormones, including the biologically
active form of vitamin D (1,25-dihydroxyvitamin D3),
parathyroid hormone (PTH), and calcitonin. Fibro-
blast growth factor member 23 (FGF23) has also been
identified as essential in the regulation of Ca2+ and Pi
homeostasis [44]. The vast majority of whole body
Ca2+ and Pi is stored as the mineral hydroxylapatite
in the skeleton. In blood, 45% of Ca2+ is present in
a free, ionized form, 45% is bound to proteins, and
a small fraction, 10%, forms complexes with citrate,
sulfate, and phosphate anions. PTH, 1,25(OH)2D3,
and estrogen exert their effect on renal-mediated Ca2+
handling by altering, at the transcriptional level, the
expression of Ca2+ transporters [45]. PTH maintains
a physiological balance of calcium and phosphate
concentrations by binding to its receptor on the plas-
ma membrane of cells in bone and kidney. It signals
through multiple pathways, including protein kinas-
es A and C, although a preference for certain path-
ways is apparent in each organ and function [46]. The
calcium-sensing receptor is a G-protein-coupled, sev-
en-pass transmembrane molecule present in the par-
athyroid gland. Kidney is a key site to co-ordinate
calcium homeostasis by regulating the release of PTH
from the parathyroid glands [47].
It is known that the osteocyte and bone lining cells,
under certain physiologic conditions, can participate
in mobilizing calcium from the skeleton to maintain
calcium balance [48–51]. When mineralization is re-
quired, tissue non-specific alkaline phosphatase, an
enzyme associated with skeletal and cartilage miner-
alization, cleaves orthophosphates from polyphos-
phates. The hydrolytic degradation of polyphosphates
in the calcium-polyphosphate complex increases or-
thophosphate and calcium concentrations and there-
fore it favours apatite mineral formation. The corre-
lation of alkaline phosphatase with this process may
be explained by the destruction of polyphosphates in
calcifying cartilage and areas of bone formation [52].
Bone as a source of adult stem cells
Under specific environmental conditions, self-renew-
ing (Figure 2), pluripotent stem cells give rise to os-
teoprogenitor cells in various tissues. BM contains
a small population of mesenchymal stem cells, distinct
from the hematopoietic stem cell population that gives
rise to blood cell lineages that are capable of giving
rise to bone, cartilage, adipose, or fibrous connective
tissue. Commitment of these mesenchymal stem cells
to the osteoblast lineage requires the activation of the
Wnt/b-catenin pathway and associated proteins [53].
The Wnt system is also important in chondrogenesis
and hematopoiesis and may be stimulatory or inhibi-
tory at different stages of osteoblast differentiation.
Cell-based therapy (Figure 3) could soon become
a new strategy to treat a wide array of clinical condi-
tions. The use of adult stem cells has major advan-
tages: (a) adult stem cells can be isolated from pa-
tients, thus overcoming the problems with immuno-
logical rejection, and (b) the risk of tumor formation
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is greatly reduced compared to the use of embryonic
stem cells [54].
Adult stem cells are clonogenic, self-renewing, and
pluripotent cells with a plasticity to differentiate into
cell types of the particular tissue in which they reside,
and often to trans-differentiate into different types
of tissues [55]. Adult stem cells are usually located in
a specific cellular niche, which determines the status
of stem cell activation, ensuring a balance between
maintenance of the stem cell pool and production of
progenitor cells engaged in tissue differentiation [56].
Hematopoietic stem cells (HSCs), which can be iso-
lated from BM, are among the best characterized
adult stem cells and the stem cells being currently used
in the clinics. Some other stem cells are also used,
but in the preclinical trials. BM also accommodates
stromal cells, mesenchymal stem cells, and various
blood cells at different stages of maturation, as well
as their progenitors. HSCs constitute only a small frac-
tion of BM population (1 in 104 to 1 in 108 of BM
nucleated cells) [57]. HSCs are able to renew them-
selves or differentiate into precursors, which produce
specialized hematopoietic cells, including lympho-
cytes, dendritic and natural killer cells, megakaryocytes,
erythrocytes, granulocytes, and macrophages [58]. Cells
in the hematopoietic hierarchy have diverse differen-
tiation potential and self-renewal capacities, and are
able to cope with the high demand to continuously pro-
duce large numbers of blood cells. The first progeny
of HSCs are multipotent progenitors that retain the
ability to differentiate into all hematopoietic lineages
but show a lower capacity to proliferate [59]. Human
HSCs are known to exhibit CD34+, Thy1+, CD38low/–,
C-kit–/low, CD105+, Lin- phenotype [60, 61].
In 1998, Ferrari et al. [62] reported that mouse
bone-marrow-derived cells give rise to skeletal mus-
cle cells when transplanted into damaged mouse
Figure 3. Bone marrow-derived adult stem cells participation in organs regeneration
Figure 2. Bone marrow as a source of adult stem cells.
Sc34+ — hematopoietic stem cells; Msc — mesenchymal
stem cells
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muscle. Thereafter, transplanted bone marrow cells
were reported to generate a wide spectrum of differ-
ent cell types, including hepatocytes [63], endothe-
lial, myocardial [64–66], neuronal, and glial cells [67,
68]. Moreover, HSC can produce cardiac myocytes
and endothelial cells [69], functional hepatocytes [70],
and epithelial cells of the liver, gut, lung, and skin
[71]. Mesenchymal stromal cells (MSC) of the bone
marrow can generate brain astrocytes [72] and some
other cell types. Nevertheless, the transformation of
transplanted bone marrow cells is still a matter of
debate, and pluripotency of these cells has not been
convincingly demonstrated in many cases.
Different types of stem cells can be combined at
progenitor-committed stages, thus greatly enhancing
the therapeutic outcome [73] and ultimately leading
to the rejuvenation of the whole organ.
Understanding the basic molecular mechanisms
underlying cell fate switching of adult stem cells will
be essential to ensure their safe use in regenerative
medicine. In the near future, it will most likely be
possible to transplant genetically modified stem cells
that carry a set of genes critical for their various func-
tions, e.g. trans-differentiation, that are under exter-
nally regulated promoters [74] and, depending on the
therapeutic requirements, direct their differentiation
into desired cell populations.
Recent studies on the plasticity of murine myo-
tubes [75] and other cells derived from adult tis-
sues suggest that dedifferentiation may be possible
in mammals [76]. At the molecular level, MSX1
(AKA Msh homeobox protein) has been identified
as a possible factor involved in dedifferentiation
processes in human cells [75, 76]. Another small
molecule, reversine, has been shown to induce
murine myogenic lineage-committed cells to be-
come multipotent mesenchymal progenitor cells
that can proliferate and re-differentiate into bone
and fat cells [77]. Epigenetic cell changes are prob-
ably involved and may be mediated by signals re-
ceived from the injured cells.
Adult stem cells have the advantage of being ob-
tainable using relatively noninvasive, autologous har-
vest methods. They are also the most promising choice
for the majority of clinical purposes. Bone marrow
stromal cells have attracted the attention of many sci-
entists interested in cellular strategies in the repair of
neural tissue [78–81]. These mesenchymal stem cells
are harvested from the long bones, and when placed
in culture medium containing the appropriate cytok-
ine cocktail, transdifferentiate into Schwann cell-like
phenotype [82].
The term multipotent mesenchymal stromal cell
(MSC) has recently been coined to describe this cell
type [83, 84], although, in the majority of scientific
publications, they have been generally referred to as
mesenchymal stem cells [85]. Adult mesenchymal
stem cells can be isolated from bone marrow or mar-
row aspirates, and because they are culture-dish ad-
herent, they can be expanded in culture while main-
taining their multipotency. MSCs have been used in
preclinical models for tissue engineering of bone, car-
tilage, muscle, marrow stroma, tendon, fat, and other
types of connective tissues [86]. MSCs secrete a broad
spectrum of bioactive macromolecules that are both
immunoregulatory and serve to structure regenerative
microenvironments in fields of tissue injury. Horwitz
et al. have reported the use of MSCs for the repair of
bone in patients with osteogenesis imperfecta [87].
Bone as a source of self restoring and healing
Every cell in the body has a specific half-life. Every
cell reaches its maturity and subsequently dies. Red
blood cells have half-lives of 60–90 days and arise in
a multi-step lineage from the hematopoietic stem
cell (HSC). The progenitor cells furnish the replace-
ment units for normal cell death. The normal half-
lives of mature cells thus provide a mechanism for
rejuvenating living tissue with fresh, functional cell
units [86]. This allows the replacement of cells that
could be non-functional, contain mutations, and sub-
stitute with cells slightly different from the expired
cells. These changes over time are referred to as ag-
ing. Adult MSCs are responsible for the replacement
of osteoblasts that in humans have half-lives of 8–10
days. Loss of bone mass results from the diminution
of regenerative units in the marrow. The capacity of
culture-expanded marrow-derived MSCs to differ-
entiate into bone, cartilage, etc. is independent of
the age of the donors. Bone density and bone mass
are dependent on the conversion of MSCs into os-
teoblasts that fill the pits of osteoclast-resorbed bone.
The niche where MSCs actually reside in marrow is
not known.
Since MSCs can differentiate into distinctive mes-
enchymal phenotypes, they have been used to restruc-
ture tissues when encased in tissue-specific scaffolds
and implanted into different tissue sites. For exam-
ple, in rodents, dogs and humans, autologous mar-
row MSCs have been delivered to long-bone repair
sites in calcium phosphate porous ceramics to pro-
duce morphologically and biomechanically superior
bone [88]. Others have used marrow MSCs in hyalu-
ronan and polymeric scaffolds for cartilage repair [89].
At least three different methods have been employed
for using MSCs in scaffolds. MSCs have been loaded
into the scaffolds in vitro and, after a short incuba-
tion to insure attachment, the cell-scaffold compos-
ites were implanted. Another way is to incubate the
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cell-scaffold composite in differentiation medium to
stimulate MSC progression into a specific lineage, and
after 7–14 days, the composite is implanted into ortho-
topic sites [90]. The last approach is to implant scaf-
folds, to which targeted cells are able to attach to
docking sites, or to implant scaffolds with the includ-
ed cells in protective coats, and allow the scaffold to
mature in vivo [91]. All of these techniques have re-
sulted in well-integrated, newly differentiated bone
tissue. These approaches have been used in various
animal models and in limited numbers in human be-
ings [88]. However, no human MSC-based tissue en-
gineering technology is currently clinically available.
MSCs secrete bioactive factors that inhibit scar-
ring and apoptosis, and stimulate angiogenesis and
mitosis of tissue-intrinsic stem and progenitor cells.
This complex, versatile activity due to the secretory
activity of MSCs is known as ‘trophic activity’ [86].
Mesenchymal stromal cells show great promise to
become biological therapeutic agents for a diverse
range of medical needs. Natural chemo-attractive
mechanisms result in the recruitment of MSCs from
remote areas to sites of tissue damage in order to
establish a reparative/regenerative microenvironment.
The age of the individual patient, the extent of tissue
damage, and the local and whole body quantity of
MSCs probably play a role in the rate and extent of the
repair and/or regeneration of damaged tissue. Various
techniques of direct delivery or manipulative targeting
of MSCs to sites of tissue damage may, in future, lead
to profound control of damage, cell death, scarring,
and subsequent regeneration of various tissues.
Total joint replacement of the upper and lower
extremities is one of the most efficacious, cost effec-
tive interventions in orthopaedic surgery. This type
of procedure alleviates pain and improves function
in a consistent fashion. Immediately after the implan-
tation, articulating and non-articulating surfaces be-
gin to wear and generate wear particles. These parti-
cles are generally distributed locally within the joint
itself; they often may be found in the regional lymph
nodes, and in some cases systemically. Periprosthetic
osteolysis may undermine the bone bed and compro-
mise the stability of the implant. Idiosyncratic immune
reactions may also occur.
Over the weeks and months following a joint re-
placement, the trabecular callus surrounding implants
undergoes successful osseointegration remodeling to
form a more consolidated mature structure that can
transmit load more effectively. Stable implants that
abut cortical bone can osseointegrate directly via
mesenchymal osteoprogenitor cells from the marrow
and endosteum [92]. Stable implants with a fibrous
or cartilagenous encapsulation layer can undergo so-
called ‘primary bone healing’ directly, with metapla-
sia of the encapsulation tissue to bone.
MSCs are potentially immunoprivileged; therefore
their implantation in an allogeneic setting has been
used to facilitate tissue repairs for bone and cartilage
defects. Cell therapy using adult stem cells is also
a potential approach for treating degenerative disk
disease [93].
Bone-related pathology
Bone loss results from the direct effects of inflamma-
tion, poor nutrition, reduced lean body mass, immo-
bility, and the effects of treatments, especially with
glucocorticoids [94]. Inflammatory disease can in-
crease bone resorption and decrease bone formation,
but most commonly it impacts on both of these pro-
cesses, resulting in an uncoupling of bone formation
from resorption in favour of excess resorption.
Glucocorticoids are commonly used to treat many
inflammatory diseases. They frequently have major
adverse effects on bone that is difficult to separate
from the effects of inflammation itself. Inflammation
also impacts the control of reproductive hormones,
leading frequently to hypogonadism in both men and
women. Inflammation influences the secretion and
action of PTH, which can lead to an increase in bone
resorption. In the adult skeleton, the combination of
many factors, such as the rate of bone turnover, col-
lagen matrix, structure, geometry, and density, deter-
mine the bone’s overall mechanical competence.
Defects in these parameters can result in diseases such
as osteoporosis, osteopetrosis, osteogenesis imperfec-
ta, and Paget’s disease [24].
Consistent with the anabolic effects of mechani-
cal stimuli, the reduction or removal of mechanical
loads results in bone atrophy, altering the mass, mor-
phology, cellular activity, and its material properties.
In humans, much of the understanding of disuse-in-
duced bone loss comes from investigations document-
ing the effects of space flight (microgravity) [95–97]
and prolonged bed rest [96, 98, 99]. During space trav-
el, the removal of gravitational and most functional
loads triggers pronounced bone atrophy, with astro-
nauts losing bone mineral at a rate of approximately
1–2% per month [97]. The atrophy is site-specific, with
greater decay generally observed in the lower appen-
dicular skeleton than the spine, and type-specific, with
trabecular bone removal three to five times greater
than that of cortical bone [98]. Bed rest studies have
yielded similar results, showing that the bone miner-
al density (BMD) of healthy males confined to bed
rest for 17 weeks decreases by 0.9–1.3% per month in
the tibia, femur, and lumbar spine [98, 100].
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During functional loading, the complete strain
state of any given piece of bone tissue is typically very
complex, but it can be described in general terms by
two predominant components: normal strains cause
volumetric changes in the tissue, while shear strains
cause angular deformations.
When changes in remodeling events are compared
between loading regimes inducing predominantly shear
or predominantly normal strains, it becomes clear that
bone tissue can readily differentiate between different
kinds of deformation; even though bone cells are re-
sponsive to both normal and shear strains, only normal
strains increase the degree of intracortical turnover [101].
The development of effective biomechanical interven-
tions in areas such as orthodontics, craniofacial repair
or osteoporosis will require the identification of the spe-
cific components of the bone’s mechanical environment
that are anabolic, catabolic, or anti-catabolic [102].
Bone responds to a great variety of mechanical sig-
nals. Both high- and low-magnitude stimuli can be sensed
by the skeleton. The ability of physical signals to influ-
ence bone morphology is strongly dependent on the sig-
nal’s magnitude, frequency, and duration. Bone’s sensi-
tivity to the application and removal of mechanical sig-
nals is under tight control of the genome. Bone loss
modulated by the removal of weight-bearing activities
is profoundly influenced by a number of factors such as
genetics, gender, and baseline morphology.
The bone mass loss associated with aging can be
reduced by the implementation of certain exercise
programs in adults and the elderly [103]. Several train-
ing methods have been used in prospective studies to
improve BMD. Not all exercise modalities have shown
positive effects on bone mass. For example, unload-
ed exercise such as swimming has no impact on bone
mass, while walking or running has only a limited
positive effect. On the other hand, even a relatively
small amount of high impact exercise appears to be
the most efficient for enhancing bone mass, although
this has not been proven in postmenopausal women.
Impact and resistance exercise should be advocated
for the prevention of osteoporosis. To reduce the like-
lihood of falling and its associated morbidity and
mortality of patients with osteoporosis, weight-bear-
ing exercise in general, and resistance exercise in par-
ticular, along with exercises targeted to improve bal-
ance, mobility and posture, should be recommended.
Obesity is protective for the skeleton, whereas low
body weight in elders is a major risk factor for frac-
tures [104]. The hypothalamus modulates fat and bone
via the sympathetic nervous system by regulation of
appetite, insulin sensitivity, energy use, and skeletal
remodeling. In the bone marrow, fat and bone cells
arise from the same stem cells.
Osteoporosis, a severe bone loss in which bones
become increasingly porous and easy to fracture, has
become one of the major health and socio-economic
problems in many countries. It is estimated that more
than 200 million people worldwide (1 in 3 women and
1 in 12 men over the age of 50) suffer from osteoporo-
sis, with three to four times as many being at risk be-
cause of low bone mass [105]. Osteoporosis-related
fractures often begin a downward spiral in health and
independence for the elderly.
Osteoporosis is a classical age-related disease that
affects women more often than men [106]. Estrogen
deficiency has direct, as well as indirect, impact on
bone metabolism. Osteoporosis is common, costly,
and morbid. Its prevalence is increasing as the popu-
lation ages.
Our understanding of osteoblast differentiation
and local regulation has increased over recent years
through the discovery of the Wnt signaling pathway
and its antagonists. The Wnt family of glycoproteins
represents a major signaling pathway that is involved
in cellular differentiation [107].
Scientific understanding of osteocytes and their
role in bone metabolism has significantly increased
in recent years. The osteocyte is a nonproliferative,
terminally differentiated cell of the osteoblast lineage
[108]. It is the most abundant cell type in bone, and
resides in the lacuna/canalicular system. There is
strong evidence supporting its role in the control of
local bone remodeling. The surface area of the lacu-
na/canalicular system is large — more than 100 times
that of the trabecular bone surface. The canalicular
system of communication for the osteocytes is simi-
lar to that of the nervous system. It is composed of
a large number of low activity cells connected through
the canaliculi, which, it is hypothesized, serve as an
efficient way to transmit signals over long distances.
The osteocytes are surrounded within their lacunae by
proteoglycans that assist in the amplification of fluid
flow-derived mechanical signals. Each osteocyte has
a cilium extending from its cell cytoplasm, which may
also translate the fluid flow signal to the osteocyte. It
has long been known that mechanical stress induced by
weight-bearing exercise increases osteoblast activity.
The stimuli responsible for the osteocyte’s action
have not been fully characterized. Recently discov-
ered sclerostin is an example of an osteocyte-derived
protein that plays an important role in the inhibition
of bone formation. Sclerostin is one of the Wnt sig-
naling antagonists known to inhibit osteogenesis [109].
This aspect of osteocyte biology may be very impor-
tant for the development of novel anabolic agents to
treat osteoporosis. The current therapies for os-
teoporosis include anti-resorptive treatment such as
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bisphosphonates, hormone replacement, and selective
estrogen receptor modulators [11]. The search for new
anabolic therapies is focused on biological pathways in-
volved in the stimulation of the osteoblast lineage cells
to differentiate from a progenitor cell, to proliferate fast-
er, and to produce more organic matrix proteins. Sever-
al signaling factors, including BMPs, PTH, endothelin,
fibroblast growth factors, steroidal hormones, insulin-
-like growth factors, and prostaglandin agonists have
emerged as crucial in the regulation of osteoblast matu-
ration, but the Wnt family of ligands has arguably gen-
erated the most interest and excitement in recent years.
Wnts are cysteine-rich, secreted glycoproteins that acti-
vate cell-surface-receptor-mediated signaling pathways
to control gene expression, cell fate determination, pro-
liferation and migration. Modulation of Wnt signaling
pathways has emerged as a promising and feasible strat-
egy to increase bone density [110, 111].
Nuclear hormone receptors represent a major
group of regulatory factors that control critical pro-
cesses of bone growth and metabolism [34, 112]. It is
well known that male bones have higher mineral den-
sity and a lower risk of fracture or osteoporosis than
female bones [113]. A decrease in testosterone level
is associated with many symptoms and signs of aging,
such as decrease in muscle mass and strength, cogni-
tive decline, reduction of bone mass, and increase in
(abdominal) fat mass [114].
Although genetic predisposition, age, race, and
ethnicity as influences on bone structure cannot be
modified, other factors such as nutrition, physical ac-
tivity, and life style choices can [13]. Promoting
a healthy lifestyle, regular weight-bearing physical ac-
tivity, and a healthy diet with optimal calcium and
vitamin D intake has been proved to be the effective
way to achieve a maximal peak bone mass.
Conclusion
This review highlights the developments in bone biol-
ogy in recent years. We believe that in the near future,
scientific advances in this field will lead to improve-
ments in the prevention and treatment of many bone
diseases, and will expand the bone marrow-derived
adult stem cell-based therapy into more diseases.
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